Key Angel® Catheter Article Publication and Ongoing Pivotal Investigation Progress of the Angel® Catheter Clinical Trial
GOLDEN, Colo., Oct. 8, 2015 /PRNewswire/ -- BiO2 Medical is pleased to announce the publication of key clinical data on the use of the Angel® Catheter in Europe. ...
BiO2 Medical Executes Q4 2013 Commercialization Strategy for the Angel® Catheter, Signing Distribution Partnership Agreements in Key European and Middle Eastern Geographies
BiO2 Medical has achieved Q4 2013 global expansion goals for the Angel® Catheter, a novel Central Venous Catheter (CVC) with a permanently attached retrievable Inferior Vena Cava (IVC) filter to provide Pulmonary Embolism (PE) protection for critically ill patients. The Angel® Catheter is the first ...
Partnership offers BiO2 Medical a hydrophilic and lubricious coating to enhance ease of placement and reduce access site trauma for the Angel® Catheter, a central venous access catheter (CVC) with a permanently attached inferior vena cava (IVC) filter. DSM a global leader in biomedical materials ...
BiO2 Medical Inc. Prophylactic Pulmonary Embolism Protection Hospitalized patients are at the greatest risk for a fatal pulmonary embolism within the first 10 days after admission, but traditional inferior vena cava filters to prevent PEs if anticoagulant therapy is contraindicated and/or ineffective are not typically placed in ...